E208 - A Look Back at This Year in Psychopharmacology with Dr. Roger McIntyre

NEI Podcast

Content provided by Neuroscience Education Institute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Neuroscience Education Institute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

9M ago 1:08:42

MP3•Episode home

What were some new treatments approved by the FDA? What did we learn about the long-term safety of methylphenidate in childhood ADHD? Are there benefits to long-term maintenance treatment with antidepressants in bipolar disorder? What did we learn about the safety and efficacy of subcutaneous racemic ketamine for treatment-resistant depression and MDMA for PTSD? In this episode, Dr. Andrew Cutler and Dr. Roger McIntyre address these questions and so much more about this past year in psychopharmacology.

Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function, and medical comorbidity. His work broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.   

Resources:

This Month in Psychopharmacology

233 episodes